Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer

Read full text
Authors: Sirui Weng, Lachlan Cain, James Comben, Y. C. Zhang, Timothy J. Semple, Sara Alaei, David Yoannidis, Luciano Gastón Martelotto, Catherine A Mitchell, Anupama Pasam, Richard J. Young, Benjamin Blyth
+20 more Joy Hendley, Yuzhou Feng, Heather Thorne, Roslyn Wallace, Joanna Chan, Julia Como, Lisa Devereux, Himisha Beltran, Daniel Wetterskog, Scott Williams, Anthony T. Papenfuss, Belinda S. Parker, Paul Joseph Neeson, Gerhardt Attard, David Alan Quigley, David L. Goode, Richard B. Pearson, Luc Furic, Anna Trigos, Shahneen Kaur Sandhu
Cited by: 1
References: 124

Abstract

The evolution to metastatic disease is a major determinant of cancer mortality. Cancer evolution involves a complex interplay between intrinsic genetics and transcriptional alterations and the microenvironment. To define mechanisms underpinning metastatic heterogeneity in late-stage disease, we focus on metastatic castration-resistant prostate cancer and employed single-cell multi-omics and whole-genome sequencing to deeply profile 34 metastatic lesions obtained from 9 patients through rapid autopsy. We find evolutionary convergence of intra-tumour heterogeneity, characterised by recurrent tumour populations acting as critical functional components of the tumour ecosystem, irrespective of clonal and microenvironmental backgrounds. We find little evidence of the microenvironment driving transcriptional heterogeneity, but there are signatures of co-adaptation between the microenvironment and tumour cells. In contrast, clonal evolution primarily foster widespread transcriptional changes that did not result in de novo functional states. Intra-patient functional convergence of tumour ecosystems across metastases indicates system-level selection pressures that drive the heterogeneity landscape of metastatic castration-resistant prostate cancer. Our findings reveal functional evolutionary convergence of metastatic disease into distinct intra-tumour subpopulations, identifying critical determinants for therapeutic targeting.

Fields of Study & Subjects

Prostate Cancer Treatment and Research Cancer Genomics and Diagnostics Melanoma and MAPK Pathways

Publication details

Journal / source
Nature Communications
Publisher
Springer Science and Business Media LLC
Volume
17
Issue
1
Publication date
19 June 2026
Language
EN